{"id":"W3084155739","doi":"10.1038/s41416-020-01041-x","title":"Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer","year":2020,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"National Cancer Institute; Takeda Oncology; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Tolerability; Endometrial cancer; Medicine; Pharmacodynamics; Renal cell carcinoma; Pharmacokinetics; Rash; Internal medicine; Bladder cancer; Urology; Dosing; Cancer; Carcinoma; Oncology; Gastroenterology; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003544216,0.0002665584,0.0006928057,0.0001835217,0.00004810882,0.00004914149,0.0003790179,0.0001432526,0.0002122717],"category_scores_gemma":[0.0002511732,0.0002548625,0.0001020217,0.0006178782,0.00009300569,0.00006153283,0.00006616402,0.0004183037,3.258561e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001440836,"about_ca_system_score_gemma":0.0009647135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007882387,"about_ca_topic_score_gemma":0.008851558,"domain_scores_codex":[0.9973763,0.0002070817,0.0009915906,0.0004747942,0.000559936,0.0003903015],"domain_scores_gemma":[0.9983929,0.00003265564,0.0007030608,0.0002051466,0.0003909262,0.0002752966],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02841332,0.003671479,0.004593618,0.00005006904,0.0002232957,0.00104513,0.0007698954,0.006959562,0.8788005,3.058716e-7,0.000945673,0.07452722],"study_design_scores_gemma":[0.1210784,0.04037237,0.001890934,0.001524641,0.0002286568,0.000295427,0.002045787,0.0002314277,0.826789,0.000005694496,0.004768398,0.0007693269],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888501,0.009872014,0.0001446126,0.0001026078,0.0003619851,0.0005151292,0.0001343523,0.000006693719,0.00001254957],"genre_scores_gemma":[0.9953802,0.002501434,0.0002926369,0.0002907162,0.001356707,0.00007564529,0.00001523025,0.00006328784,0.0000241773],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09266505,"threshold_uncertainty_score":0.9999903,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02676153683504138,"score_gpt":0.3543512937309712,"score_spread":0.3275897568959298,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}